Work

294P Targeted treatment of pediatric leukemia with anti-IL7Rα chimeric antibody

Year: 2025

Type: article

Abstract: Acute Lymphoblastic Leukemia (ALL) is a hematological malignancy of B and T cells and the leading cause of cancer-related deaths in children. Approximately 10% of T-ALL and 2% of B-ALL cases carry activating mutations in the interleukin-7 receptor gene (hIL7Rα), a protein essential for lymphocyte development that can acquire oncogenic potential, making it a relevant therapeutic target.

Source: Immuno-Oncology Technology

DOI: 10.1016/j.iotech.2025.101493

Authors: J.M.S. Feitoza, F.M.D.S. De Lima, J.F. Fonseca, A. Paula Sousa Ferreira, M. Cavalcante, P. Pini Zenatti

Institutions: Universidade Estadual de Campinas (UNICAMP), Centro Infantil Boldrini

Language: English

Topic: Acute Lymphoblastic Leukemia research

Subfield: Public Health, Environmental and Occupational Health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,340